A feline model of experimentally induced islet amyloidosis

American Journal of Pathology

Volumn 157, Issue 6, 2000, Pages 2143-2150

  Hoenig, Margarethe ^a   Hall, Gregory ^a   Ferguson, Duncan ^a   Jordan, Katherine ^b   Henson, Michael ^b   Johnson, Kenneth ^b   O'Brien, Timothy ^b  

^a UNIVERSITY OF GEORGIA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLIN; AMYLOID; DEXAMETHASONE; GLIPIZIDE; GROWTH HORMONE; INSULIN; ISOPHANE INSULIN;

AMYLOIDOSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAT; EXPERIMENTAL MODEL; HYPERGLYCEMIA; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET DISEASE; PANCREAS RESECTION; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN SECRETION; TRANSGENIC ANIMAL;

EID: 0033638235     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)64852-3     Document Type: Article

References (35)

1. Amyloidosis of the islets of Langerhans, a study of islet hyalin in diabetic and nondiabetic individuals
2. Quantitative studies of amyloid in the islets of Langerhans
3. Das Amyloid der Langerhansschen Inseln und seine Beziehung zum Diabetes Mellitus
4. Islet amyloid, islet amyloid polypeptide and diabetes mellitus
5. Pancreatic pathology in non-insulin dependent diabetes (NIDDM)
6. Animal model of human disease: Spontaneous diabetes mellitus-islet amyloid complex in adult cats
7. Spontaneous diabetes mellitus in Cynomolgus monkeys: Morphometric analysis of islet amyloid and islet cells
8. Impaired glucose tolerance is associated with increased islet amyloid polypeptide (IAPP) immunoreactivity in pancreatic beta cells
9. Amyloid fibrils in human insulinoma and islets of Langerhans of the diabetic cat are derived from a novel neuropeptide-like protein also present in normal islet cells
10. Islet amyloid in type 2 human diabetes mellitus and adult diabetic cats is composed of a novel putative polypeptide hormone
11. Effects of meal ingestion on plasma amylin concentration in NIDDM and nondiabetic humans
12. Evidence of cosecretion of islet amyloid polypeptide and insulin by β-cells
13. Islet amyloid polypeptide (IAPP) and insulin secretion from isolated perfused pancreas of fed, fasted, glucose-treated, and dexamethasone-treated rats
14. Intracellular amyloid associated with cytotoxicity in COS-1 cells expressing human islet amyloid polypeptide
15. Pancreatic islet cell toxicity of amylin associated with type-2 diabetes mellitus
16. Neurotoxicity of human amylin in rat primary hippocampal cultures: Similarity to Alzheimer's disease amyloid-β neurotoxicity
17. Different amyloidogenic peptides share a similar mechanism of neurotoxicity involving reactive oxygen species and calcium
18. Insulin-like growth factor I protects and rescues hippocampal neurons against beta-amyloid- and human amylin-induced toxicity
19. Treatment with growth hormone and dexamethasone in mice transgenic for human islet amyloid polypeptide causes islet amyloidosis and β-cell dysfunction
20. Spontaneous diabetes mellitus in transgenic mice expression human islet amyloid polypeptide
21. Islet amyloid formation associated with hyperglycemia in transgenic mice with pancreatic beta cell expression of human islet amyloid polypeptide
22. Islet amyloid-associated diabetes in obese A(vy)/a mice expressing human islet amyloid polypeptide
23. Impairment of glucose tolerance in hyperthyroid cats
24. The diagnostic utility of glycosylated hemoglobin in the cat
25. Increased plasma levels of islet amyloid polypeptide in patients with primary hyperparathyroidism
26. Pituitary-diabetes in the cat: Recovery following insulin or dietary treatment
27. Feline insular amyloid: Association with diabetes mellitus
28. Immunohistochemical morphometry of pancreatic endocrine cells in diabetic, normoglycemic glucose-intolerant and normal cats
29. Effect of insulin treatment on circulating islet amyloid polypeptide in patients with NIDDM
30. Plasma concentrations of islet amyloid polypeptide after glucagon administration in type 2 diabetic patients and non-diabetic subjects
31. Changes in amylin and amylin-like peptide concentrations and b-cell function in response to sulfonylurea or insulin therapy in NIDDM
32. Islet amyloid polypeptide: A review of its biology and potential roles in the pathogenesis of diabetes mellitus
33. Quantitative immunohistochemical analysis of islet amyloid polypeptide (IAPP) in normal, impaired glucose tolerant, and diabetic cats
34. Islet amyloid polypeptide (IAPP) on human insulinomas: Evidence for intracellular amyloidogenesis
35. Management of the adult onset diabetic with sulfonylurea drug failure